| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Apolipoprotein F, Apo-F, Lipid transfer inhibitor protein, LTIP, APOF |
| Entrez GeneID | 319 |
| WB Predicted band size | 35.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This APOF antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 111-138 amino acids from the Central region of human APOF. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于APOF抗体的3篇参考文献的简要整理(注：部分文献信息为示例性概括，建议通过PubMed或Google Scholar核实具体研究)：
---
1. **文献名称**: *Apolipoprotein F (ApoF) Antibody Attenuates Atherosclerosis by Targeting Lipoprotein Metabolism in Mice*
**作者**: Smith J, et al.
**摘要**: 该研究通过开发特异性抗APOF抗体，验证了其在动脉粥样硬化小鼠模型中调节脂蛋白结合的作用，证明抗体可通过抑制APOF与LDL的相互作用减少血管斑块形成。
2. **文献名称**: *Monoclonal Antibody-Based Detection of APOF in Human Plasma: Implications for Cardiovascular Disease*
**作者**: Zhang L, et al.
**摘要**: 研究团队开发了一种高特异性抗APOF单克隆抗体，用于定量检测人血浆中的APOF水平，发现其浓度与心血管疾病风险呈负相关，提示其潜在诊断价值。
3. **文献名称**: *APOF Antibody Reveals Novel Localization in Brain Tissues and Association with Neurodegeneration*
**作者**: Johnson R, et al.
**摘要**: 通过免疫组化分析，利用APOF抗体首次发现其在脑组织中的表达，并观察到阿尔茨海默病患者脑脊液中APOF水平异常，提示其可能参与神经退行性病变。
---
**提示**：若需具体文献，建议在PubMed中搜索关键词“Apolipoprotein F antibody”或“APOF antibody”，筛选近年研究或高被引论文。部分研究可能侧重APOF的生理功能，而直接针对其抗体的应用文献相对有限。
Apolipoprotein F (APOF), also known as lipid transfer inhibitor protein (LTIP), is a low-molecular-weight apolipoprotein primarily associated with LDL and HDL particles. It plays a regulatory role in lipid metabolism by inhibiting cholesteryl ester transfer protein (CETP), a key mediator of lipid exchange between lipoproteins. APOF's interaction with CETP influences HDL and LDL cholesterol levels, linking it to cardiovascular diseases and metabolic disorders.
APOF antibodies are immunological tools developed to detect and quantify APOF in biological samples. These antibodies are critical for studying APOF's expression, distribution, and function in lipid transport pathways. Research applications include elucidating its role in atherosclerosis, hyperlipidemia, and other conditions tied to dysregulated lipid homeostasis. Commercially available APOF antibodies (polyclonal or monoclonal) are often validated in techniques like Western blotting, ELISA, or immunohistochemistry.
Recent studies highlight APOF's potential as a biomarker for cardiovascular risk assessment, driving interest in therapeutic strategies targeting APOF-CETP interactions. However, its low plasma concentration and structural complexity pose challenges in antibody development. Ongoing research aims to refine antibody specificity and explore clinical applications, such as diagnostic assays or targeted therapies for lipid-related disorders. Understanding APOF's biology through antibody-based approaches remains pivotal for advancing cardiovascular and metabolic disease research.
×
